Healthcare provider profile · identity verified

Alexander Pinkusovich, MD

Allopathic & Osteopathic Physicians|Psychiatry & Neurology|Psychiatry · BROOKLYN, NY · NPI 1801850003

Profile state: payments and partd Open Payments: 2025 Medicare Part D: 2024 Last identity check: 2026-08-10 Page data build: 2026-08-12

Verified facts

What the public records show

CMS Open Payments records show Alexander Pinkusovich, MD received $40,023.97 in general payments during 2025 across 90 reported records.

ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) accounted for 98.9% of that reported general-payment amount.

The Open Payments records used for this analysis explicitly named 4 associated products.

A separate comparison found the same explicitly named product in public Medicare Part D data: Caplyta.

ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported UBRELVY as an associated drug or biological on 299803 records involving 61203 distinct recipient NPIs. Public Medicare Part D data also shows 21 claims for Ubrelvy by this doctor in 2024.

ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported VIIBRYD as an associated drug or biological on 57 records involving 55 distinct recipient NPIs. Public Medicare Part D data also shows 210 claims for Viibryd by this doctor in 2024.

ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported VRAYLAR as an associated drug or biological on 377741 records involving 62704 distinct recipient NPIs. Public Medicare Part D data also shows 133 claims for Vraylar by this doctor in 2024.

ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported CAPLYTA as an associated drug or biological on 211855 records involving 46143 distinct recipient NPIs. Public Medicare Part D data also shows 3922 claims for Caplyta by this doctor in 2024.

These records do not establish that a payment influenced prescribing or medical care.

Payment overview · 2025

General Payments

$40,023.97

90 reported records · 4 companies

Separate record types

Research & Ownership

Research Payments (direct recipient): not present in the loaded data

Associated Research Funding (for example, named PI): not present in the loaded data

Ownership / Investment: not present in the loaded data

These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.

Who paid this doctor?

Companies in 2025 General Payments

Reported company	Canonical company	Amount	Share	Records	Year
ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.)	Unresolved — no canonical attribution shown	$39,580.60	98.9%	71	2025
E.R. Squibb & Sons, L.L.C.	Unresolved — no canonical attribution shown	$325.33	0.8%	14	2025
Ardelyx, Inc.	Unresolved — no canonical attribution shown	$75.48	0.2%	3	2025
ABBVIE INC.	Unresolved — no canonical attribution shown	$42.56	0.1%	2	2025

What were the payments for?

Payment categories

Category	Amount	Records
Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program	$32,500.00	15
Consulting Fee	$3,520.00	1
Food and Beverage	$3,359.55	72
Travel and Lodging	$644.42	2

A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.

Analysis 1 · Payment-linked products

Products named in Open Payments records

Reported product	Type	Reported company	Related amount*	Records	Year
CAPLYTA Normalized: caplyta	Drug	ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.)	$39,580.60	71	2025
Source payment records 2025-01-15 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $30.83 · Open Payments source 2025-01-29 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $24.96 · Open Payments source 2025-02-04 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $24.99 · Open Payments source 2025-02-12 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $28.13 · Open Payments source 2025-02-19 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $18.68 · Open Payments source 2025-02-20 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $129.67 · Open Payments source 2025-02-20 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $2,100.00 · Open Payments source 2025-02-27 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $125.00 · Open Payments source 2025-02-27 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $2,100.00 · Open Payments source 2025-03-09 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $28.08 · Open Payments source 2025-03-13 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $125.00 · Open Payments source 2025-03-13 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $2,100.00 · Open Payments source 2025-03-24 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $28.24 · Open Payments source 2025-03-28 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $8.80 · Open Payments source 2025-04-18 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $24.65 · Open Payments source 2025-04-24 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $2,100.00 · Open Payments source 2025-04-24 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $79.54 · Open Payments source 2025-04-30 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $27.59 · Open Payments source 2025-05-09 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $27.75 · Open Payments source 2025-05-14 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $125.00 · Open Payments source 2025-05-17 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $27.22 · Open Payments source 2025-06-05 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $30.16 · Open Payments source 2025-06-12 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $2,100.00 · Open Payments source 2025-06-12 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $107.11 · Open Payments source 2025-06-18 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $28.02 · Open Payments source 2025-07-02 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $2,200.00 · Open Payments source 2025-07-09 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $30.74 · Open Payments source 2025-07-10 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $125.00 · Open Payments source 2025-07-16 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $2,200.00 · Open Payments source 2025-07-16 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $31.25 · Open Payments source 2025-07-28 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $29.90 · Open Payments source 2025-08-04 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $125.00 · Open Payments source 2025-08-07 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $127.27 · Open Payments source 2025-08-08 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $28.10 · Open Payments source 2025-08-13 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $2,200.00 · Open Payments source 2025-08-15 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $27.16 · Open Payments source 2025-08-28 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $2,200.00 · Open Payments source 2025-09-03 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $27.33 · Open Payments source 2025-09-05 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $7.14 · Open Payments source 2025-09-08 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $125.49 · Open Payments source 2025-09-11 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $34.48 · Open Payments source 2025-09-18 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $2,200.00 · Open Payments source 2025-09-22 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $30.32 · Open Payments source 2025-09-24 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $10.10 · Open Payments source 2025-10-04 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $24.29 · Open Payments source 2025-10-04 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $24.29 · Open Payments source 2025-10-04 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $275.45 · Open Payments source 2025-10-04 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $46.64 · Open Payments source 2025-10-04 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $52.94 · Open Payments source 2025-10-04 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $59.43 · Open Payments source 2025-10-04 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $368.97 · Open Payments source 2025-10-08 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $29.46 · Open Payments source 2025-10-09 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $125.97 · Open Payments source 2025-10-12 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $23.50 · Open Payments source 2025-10-15 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $103.93 · Open Payments source 2025-10-17 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $31.61 · Open Payments source 2025-10-23 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $2,200.00 · Open Payments source 2025-10-29 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $2,200.00 · Open Payments source 2025-11-06 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $129.98 · Open Payments source 2025-11-07 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $29.65 · Open Payments source 2025-11-13 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $107.14 · Open Payments source 2025-11-17 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $3,520.00 · Open Payments source 2025-12-03 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $28.13 · Open Payments source 2025-12-04 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $2,200.00 · Open Payments source 2025-12-06 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $7.98 · Open Payments source 2025-12-10 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $2,200.00 · Open Payments source 2025-12-11 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $100.00 · Open Payments source 2025-12-12 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $32.50 · Open Payments source 2025-12-18 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $125.00 · Open Payments source 2025-12-19 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $25.04 · Open Payments source 2025-12-22 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $2,200.00 · Open Payments source
COBENFY Normalized: cobenfy	Drug	E.R. Squibb & Sons, L.L.C.	$325.33	14	2025
Source payment records 2025-05-23 · E.R. Squibb & Sons, L.L.C. · $29.67 · Open Payments source 2025-06-06 · E.R. Squibb & Sons, L.L.C. · $34.61 · Open Payments source 2025-06-27 · E.R. Squibb & Sons, L.L.C. · $31.14 · Open Payments source 2025-07-31 · E.R. Squibb & Sons, L.L.C. · $32.41 · Open Payments source 2025-09-12 · E.R. Squibb & Sons, L.L.C. · $14.26 · Open Payments source 2025-09-12 · E.R. Squibb & Sons, L.L.C. · $10.26 · Open Payments source 2025-09-19 · E.R. Squibb & Sons, L.L.C. · $28.10 · Open Payments source 2025-10-17 · E.R. Squibb & Sons, L.L.C. · $32.86 · Open Payments source 2025-10-22 · E.R. Squibb & Sons, L.L.C. · $7.98 · Open Payments source 2025-11-07 · E.R. Squibb & Sons, L.L.C. · $4.58 · Open Payments source 2025-11-07 · E.R. Squibb & Sons, L.L.C. · $25.79 · Open Payments source 2025-11-19 · E.R. Squibb & Sons, L.L.C. · $35.61 · Open Payments source 2025-12-03 · E.R. Squibb & Sons, L.L.C. · $26.28 · Open Payments source 2025-12-12 · E.R. Squibb & Sons, L.L.C. · $11.78 · Open Payments source
IBSRELA Normalized: ibsrela	Drug	Ardelyx, Inc.	$75.48	3	2025
Source payment records 2025-02-19 · Ardelyx, Inc. · $27.67 · Open Payments source 2025-03-17 · Ardelyx, Inc. · $25.24 · Open Payments source 2025-09-08 · Ardelyx, Inc. · $22.57 · Open Payments source
LINZESS Normalized: linzess	Drug	ABBVIE INC.	$42.56	2	2025
Source payment records 2025-06-06 · ABBVIE INC. · $25.00 · Open Payments source 2025-06-06 · ABBVIE INC. · $17.56 · Open Payments source

* Product-associated amounts are non-additive because one payment record may name more than one product.

These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.

Public prescribing for products named in payments

Open Payments product	Payment year	Part D brand	Part D year	Claims	Match method	Source
CAPLYTA caplyta	2025	Caplyta	2024	3922	exact normalized	Medicare Part D

The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.

Analysis 2 · Same-company prescribing overlap

Drugs reported in other payments from the same company that also appear in Medicare Part D

This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.

Paying company	Payment year	Drug reported by same entity	Open Payments evidence	Part D	Claims	Beneficiaries
ABBVIE INC. Exact reporting entity; no affiliate inference	2025	UBRELVY open payments reported associated product	CMS Open Payments — General Payments 299803 supporting records · 61203 recipient NPIs · example record 1201352530	Ubrelvy · 2024 Exact normalized brand match · 1 Part D row	21	suppressed by CMS
ABBVIE INC. Exact reporting entity; no affiliate inference	2025	VIIBRYD open payments reported associated product	CMS Open Payments — General Payments 57 supporting records · 55 recipient NPIs · example record 1201398050	Viibryd · 2024 Exact normalized brand match · 1 Part D row	210	36
ABBVIE INC. Exact reporting entity; no affiliate inference	2025	VRAYLAR open payments reported associated product	CMS Open Payments — General Payments 377741 supporting records · 62704 recipient NPIs · example record 1201352550	Vraylar · 2024 Exact normalized brand match · 1 Part D row	133	21
ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) Exact reporting entity; no affiliate inference	2025	CAPLYTA open payments reported associated product	CMS Open Payments — General Payments 211855 supporting records · 46143 recipient NPIs · example record 1241243071	Caplyta · 2024 Exact normalized brand match · 1 Part D row	3922	607

These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.

Public Medicare Part D data

Provider-and-drug rows loaded for 2024

Brand	Generic	Claims	Beneficiaries
Caplyta	Lumateperone Tosylate	3922	607
Zolpidem Tartrate	Zolpidem Tartrate	2006	324
Namzaric	Memantine Hcl/Donepezil Hcl	1896	248
Citalopram Hbr	Citalopram Hydrobromide	1709	223
Trazodone Hcl	Trazodone Hcl	1687	243
Vilazodone Hcl	Vilazodone Hcl	1207	154
Lorazepam	Lorazepam	1024	260
Memantine Hcl	Memantine Hcl	840	128
Latuda	Lurasidone Hcl	736	112
Lurasidone Hcl	Lurasidone Hcl	712	113
Escitalopram Oxalate	Escitalopram Oxalate	694	91
Desvenlafaxine Succinate Er	Desvenlafaxine Succinate	388	42
Donepezil Hcl	Donepezil Hcl	379	51
Memantine Hcl Er	Memantine Hcl	349	49
Clonazepam	Clonazepam	328	72
Wellbutrin Xl	Bupropion Hcl	328	33
Viibryd	Vilazodone Hcl	210	36
Trintellix	Vortioxetine Hydrobromide	185	19
Temazepam	Temazepam	178	48
Eszopiclone	Eszopiclone	169	29
Alprazolam	Alprazolam	165	32
Sertraline Hcl	Sertraline Hcl	158	20
Fetzima	Levomilnacipran Hcl	135	20
Vraylar	Cariprazine Hcl	133	21
Venlafaxine Hcl Er	Venlafaxine Hcl	129	14
Aripiprazole	Aripiprazole	121	17
Doxepin Hcl	Doxepin Hcl	121	16
Mirtazapine	Mirtazapine	96	11
Duloxetine Hcl	Duloxetine Hcl	94	11
Rivastigmine	Rivastigmine	84	12
Bupropion Xl	Bupropion Hcl	77	11
Quetiapine Fumarate	Quetiapine Fumarate	77	suppressed
Olanzapine	Olanzapine	66	suppressed
Risperidone	Risperidone	59	12
Buspirone Hcl	Buspirone Hcl	52	suppressed
Fluoxetine Hcl	Fluoxetine Hcl	51	suppressed
Pristiq	Desvenlafaxine Succinate	50	suppressed
Quetiapine Fumarate Er	Quetiapine Fumarate	48	suppressed
Rexulti	Brexpiprazole	45	suppressed
Silenor	Doxepin Hcl	42	suppressed
Meclizine Hcl	Meclizine Hcl	37	suppressed
Benztropine Mesylate	Benztropine Mesylate	36	suppressed
Paroxetine Er	Paroxetine Hcl	34	suppressed
Paroxetine Hcl	Paroxetine Hcl	33	suppressed
Zaleplon	Zaleplon	32	suppressed
Gabapentin	Gabapentin	30	suppressed
Fluvoxamine Maleate	Fluvoxamine Maleate	28	suppressed
Zyprexa	Olanzapine	26	suppressed
Cymbalta	Duloxetine Hcl	25	suppressed
Exelon	Rivastigmine	24	suppressed
Lexapro	Escitalopram Oxalate	24	suppressed
Rivastigmine	Rivastigmine Tartrate	21	suppressed
Ubrelvy	Ubrogepant	21	suppressed
Ambien	Zolpidem Tartrate	20	suppressed
Effexor Xr	Venlafaxine Hcl	20	suppressed
Divalproex Sodium	Divalproex Sodium	17	suppressed
Seroquel Xr	Quetiapine Fumarate	16	suppressed
Rozerem	Ramelteon	15	suppressed
Divalproex Sodium Er	Divalproex Sodium	14	suppressed
Diazepam	Diazepam	13	suppressed
Fluphenazine Decanoate	Fluphenazine Decanoate	13	suppressed
Oxycodone-Acetaminophen	Oxycodone Hcl/Acetaminophen	13	suppressed
Acetaminophen-Codeine	Acetaminophen With Codeine	12	suppressed
Aplenzin	Bupropion Hbr	12	suppressed
Namenda Xr	Memantine Hcl	12	suppressed
Xanax	Alprazolam	12	suppressed
Celexa	Citalopram Hydrobromide	11	suppressed
Oxcarbazepine	Oxcarbazepine	11	suppressed

Timeline

Payment and prescribing data by year

Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.

Year	General Payments	Main payer	Explicit products	Company overlaps	Part D coverage
2025	$40,023.97 · 90 records	ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.)	CAPLYTA, COBENFY, IBSRELA, LINZESS	4	—
2024	—	—	—	—	Complete

Questions to ask

Questions you could discuss with your doctor

What role, if any, does Caplyta play in your treatment recommendations for me?
How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
Are there reasonable alternatives I should understand when we discuss treatment options?
How should I interpret the industry-payment records shown here in the context of my care?

These are general questions generated from reviewed templates. They are not personalized medical advice.

Sources and limitations

How to read this page

Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.

Loaded source releases

Dataset	Year	Publication	Source
CMS Open Payments — General Payments	2025	2026-06-30	Original source
Medicare Part D Prescribers by Provider and Drug	2024	2026-05-06	Original source
NPPES Data Dissemination V2	current / reference data	2026-08-10	Original source

Methodology version: 2.1

Editorial template version: 2.4

Product contract version: 2.0

Schema version: 0.7.0

Page data build: 2026-08-12T23:34:59.370714+00:00

Publication policy: eligible for indexing after public-launch controls are enabled

Full methodology · Questions & answers · Report a possible error